All In Biotech

Drug Trial Radar · NCT02867709

Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine

Last checked: Nov 19, 2026Latest source record: Mar 19, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,686 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,686

Actual

Start

Aug 26, 2016

Primary completion

Jan 25, 2018

Study completion Feb 26, 2018

Sponsor

Lead sponsor
AllerganAbbVie (ABBV)
Sponsor type
Industry
First posted
Aug 16, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the efficacy, safety, and tolerability of 2 doses of ubrogepant (25 and 50 mg) compared to placebo for the acute treatment of a single migraine attack.

Conditions

  • Migraine, With or Without Aura

Interventions

  • UbrogepantDrug

    Ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.

  • Placebo-matching UbrogepantDrug

    Placebo-matching ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Pain Freedom at 2 Hours After Initial DoseTime frame: Baseline (Predose) to 2 hours after initial dose
  2. Percentage of Participants With Absence of the Most Bothersome Migraine-Associated Symptom Identified at Baseline at 2-Hours After Initial DoseTime frame: Baseline (Predose) to 2 hours after initial dose

Locations

109 sites in 1 country. Site status is shown where the registry gives one.

  • Clinical Research Advantage, Inc./Simon Williamson Clinic

    Birmingham, Alabama

  • Clinical Research Advantage, Inc./East Valley Family Physicians, PLC

    Chandler, Arizona

  • St. Joseph's Hospital & Medical Center - Barrow Neurologic Institute (BNI)

    Phoenix, Arizona

  • Clinical Research Advantage, Inc./Central Phoenix Medical Clinic, LLC

    Phoenix, Arizona

  • Mayo Clinic Arizona, May Clinic Scottsdale

    Scottsdale, Arizona

  • Radiant Research Inc.

    Tucson, Arizona

  • Anaheim Clinical Trials, LLC

    Anaheim, California

  • Axiom Research, LLC

    Apple Valley, California

  • Hope Clinical Research

    Canoga Park, California

  • Axiom Research, LLC

    Colton, California

  • Pharmacology Research Institute

    Encino, California

  • Neuro-Pain Medical Center

    Fresno, California

  • California Headache and Balance Center

    Fresno, California

  • Sun Valley Research Center

    Imperial, California

  • Grossmont Center For Clinical Research

    La Mesa, California

  • Pharmacology Research Institute

    Los Alamitos, California

  • California Advanced Neurotherapeutic, Inc.

    Los Angeles, California

  • Cedars Sinai Pain Center

    Los Angeles, California

  • Pharmacology Research Institute

    Newport Beach, California

  • Rancho Cucamonga Clinical Research

    Rancho Cucamonga, California

  • Desert Valley Research

    Rancho Mirage, California

  • George J Rederich MD, Inc

    Redondo Beach, California

  • Artemis Institute For Clinical Research

    San Diego, California

  • Clinical Research Advantage, Inc./Cassidy Medical Group-Vista

    Vista, California

  • Clinicos, LLC

    Colorado Springs, Colorado

  • Colorado Neurological Institute

    Englewood, Colorado

  • Advanced Neurosciences Research, LLC

    Fort Collins, Colorado

  • Georgetown University Hospital

    Washington D.C., District of Columbia

  • Radiant Clinical Research

    Washington D.C., District of Columbia

  • Aventura Neurological Associates

    Aventura, Florida

  • Clinical Research South Florida

    Coral Gables, Florida

  • Avail Clinical Research, LLC

    DeLand, Florida

  • Broward Research Group

    Hollywood, Florida

  • Health Awareness, Inc.

    Jupiter, Florida

  • Neurology Associates, P.A.

    Maitland, Florida

  • LCC Medical Research Institute, LLC

    Miami, Florida

  • Well Pharma Medical Research, Corp.

    Miami, Florida

  • Panax Clinical Research

    Miami Lakes, Florida

  • Suncoast Clinical Research

    New Port Richey, Florida

  • Renstar Medical Research

    Ocala, Florida

Showing 40 of 109 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.